Pfizer has terminated a Phase II study of its CD47 immune checkpoint inhibitor, maplirpacept, due to low recruitment. In an ...

Pfizer insists that the discontinuation of the Phase II study was due to recruitment difficulties and was not linked to ...

The US Food and Drug Administration’s top vaccine official overrode agency experts in May to recommend against the broad use ...

In a recent regulatory development, the Subject Expert Committee (SEC) under the Dermatology and Allergy division of the ...

Myocarditis, when the heart muscle gets inflamed, can make it harder for the heart to pump blood possibly causing chest pain, ...

The revamped and “more anti-vax skewed ACIP committee” at the CDC “has a bone to pick with mRNA vaccines,” according to ...

The FDA has updated its warnings about potential cardiac risks associated with Pfizer and Moderna COVID-19 vaccines, ...

Another BCMA-targeted agent has arrived for the treatment of multiple myeloma. | After a delay, Regeneron’s BCMA-directed ...

A top official at the Food and Drug Administration recently overruled government scientists on the availability of two ...

Pfizer has reported positive topline outcomes from the multicentre, open-label Phase III BASIS trial of Hympavzi.

Results from the Phase III BASIS trial show that once-weekly subcutaneous Hympavzi reduced annualized bleeding rates by 93% ...

Pfizer has discontinued its Phase 1b/2 trial of maplirpacept (PF-07901801), a CD47-blocking agent, in combination with ...